Related Experiment Video
Updated: Oct 17, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
Sustained release of isoniazid in vivo from a single implant of a biodegradable polymer
P R Gangadharam1, D R Ashtekar, D C Farhi
1University of Illinois School of Medicine, Chicago 60612.
Abstract:
In order to solve the problem of poor patient compliance, attempts were made to prolong the bioavailability of antimycobacterial drugs after a single administration. A single implant of polylactic-co-glycolic acid (PLGA) co-polymer containing isoniazid ensured its sustained release up to 6 weeks. The levels are comparable with those obtained from daily doses. Homogenates of liver and lungs from animals killed at 6 weeks after a single implant showed high antimycobacterial activity against Mycobacterium tuberculosis. Sera from the implant and daily dose group animals showed no significant difference in renal, hepatic and haematological parameters. The implant caused no local or systemic toxicity.
Related Concept Videos
Modified-Release Drug Delivery Systems: Rate-Programmed II
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Modified-Release Drug Delivery Systems: Stimuli-Activated
Oral Drug Delivery Systems: Continuous-Release Systems
Oral Drug Delivery Systems: Delayed-Release Systems
Intrauterine Drug Delivery Systems

